DISCOVER study: Detecting Increased Susceptibility for Cancer in relatives by Offering genetic Variant Evaluation as Regular health care: prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21534

Enrollment

800

Registered

2021-07-20

Start date

2021-12-21

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Mainstream germline genetic testing

Other intervention

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Mannen met prostaatkanker, stadium TxNxM1; 2. Kiembaan DNA-onderzoek is besproken en aangevraagd door niet-klinisch genetische zorgprofessionals 

Exclusion criteria

Exclusion criteria: 1. Tumor DNA-onderzoek; 2. Pretest counseling door klinisch geneticus of genetische counselor; 3. Kan de Nederlandse taal niet begrijpen, spreken en schrijven

Design outcomes

Primary

Measure	Time frame
Experience of healthcare professionals and patients with the mainstreaming pathway in metastatic prostate cancer	—

Secondary

Measure	Time frame
Efficacy of the mainstreaming pathway in metastatic prostate cancer	—

Contacts

Public ContactMichiel Vlaming

University Medical Center Utrecht

M.Vlaming@umcutrecht.nl+3188 75 538 00

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)